TITAN: Phase III Trial of Apalutamide vs Placebo in Patients With Metastatic Castration-Sensitive Prostate Cancer Receiving ADT

May 31 - June 4, 2019; Chicago, Illinois
Apalutamide plus ADT significantly improved OS and rPFS vs placebo plus ADT in patients with metastatic castration-sensitive prostate cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 232 KB
Released: June 7, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Astellas and Seattle Genetics, Inc.
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Short slideset with the latest on next-generation AR inhibitors for nonmetastatic castration-resistant prostate cancer, from Clinical Care Options (CCO)

Karim Fizazi, MD, PhD Alicia K. Morgans, MD, MPH Released: July 30, 2021

Focused slideset from experts on the use of radium-223 and PSMA lutetium in the treatment of metastatic castration-resistant prostate cancer, from Clinical Care Options (CCO)

Chris Parker, MD Bertrand Tombal, MD, PhD Released: July 20, 2021

On-demand webcast on PARP inhibitor combination therapies in prostate cancer featuring 3 faculty experts presented by Clinical Care Options (CCO)

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 7, 2021 Expired: July 6, 2022

Dr. Charles J. Ryan discusses the rationale and evidence for PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: July 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue